A Vaccine for Alzheimer’s Disease? An Interview With AC Immune’s Prof Andrea Pfeifer

 

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.


Read the full story ... >>

 


About Us

At Women in Science, our goal is to build a supportive community to connect women who are in STEM fields. We are dedicated to promoting recruitment and retention of women in science, and to enlisting companies and institutions for a broad coalition of educators and employers to help bring down the barriers and empower women in their chosen fields. Find more info ... >>

Contact info

WomenInScience.com
9951 ATLANTIC BLVD., STE 105
JACKSONVILLE, FL 32225
U.S.A.
Email: staff@womeninscience.com
Phone: (904) 638-1058
Fax: (904) 212-1238

Career Network

www.postdocjobs.comwww.stemcareers.com